The treatment of kala-azar: a review with comments drawn from experience in Kenya.

dc.contributor.author	Rees, PH
dc.contributor.author	Kager, PA
dc.contributor.author	Ogada, T
dc.contributor.author	Eeftinck Schattenkerk, JK
dc.date.accessioned	2013-06-06T13:55:34Z
dc.date.available	2013-06-06T13:55:34Z
dc.date.issued	1985-03
dc.identifier.citation	Trop Geogr Med. 1985 Mar;37(1):37-46	en
dc.identifier.uri	http://www.ncbi.nlm.nih.gov/pubmed/3874454
dc.identifier.uri	http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/29396
dc.description.abstract	Pentavalent antimony (Sbv) compounds have been used in the treatment of kala azar for over 60 years. Their introduction was preceded by the use, for a few years, of SbIII compounds, especially tartar emetic. Although the exact usage of Sbv varies from country to country, with correct use, cure rates of over 90% can, in most countries, be expected. There is little problem with toxicity, though occasional unexplained deaths that do not appear to be directly due to Sbv do occur during treatment. The main second line drugs, pentamidine and amphotericin, are less effective and relatively toxic. Other second line treatments that have been used in resistant kala azar in Kenya include allopurinol, diminazene aceturate, and Sbv liposomes. Splenectomy has been used as a last resort	en
dc.language.iso	en	en
dc.publisher	University of Nairobi	en
dc.title	The treatment of kala-azar: a review with comments drawn from experience in Kenya.	en
dc.type	Article	en
local.publisher	School of medicine	en